Hoffmann-La Roche

Lineage Cell Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10, 2022

Retrieved on: 
Thursday, November 3, 2022

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its third quarter 2022 financial and operating results on Thursday, November 10, 2022, following the close of the U.S. financial markets.

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its third quarter 2022 financial and operating results on Thursday, November 10, 2022, following the close of the U.S. financial markets.
  • Lineage management will also host a conference call and webcast on Thursday, November 10, 2022, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its third quarter 2022 financial and operating results and to provide a business update.
  • Interested parties may access the conference call by dialing (800) 715-9871 from the U.S. and Canada and should request the Lineage Cell Therapeutics Call or provide conference ID number 5262180.
  • Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs.

Genentech to Present Data at ASH 2022 Showcasing Strength of Hematology Portfolio and Expanding Into New Areas to Address More Patient Needs

Retrieved on: 
Thursday, November 3, 2022

The data we are presenting reinforce our ongoing commitment to redefining treatment paradigms, improving on existing standards of care and addressing a diversity of patient and healthcare system needs.

Key Points: 
  • The data we are presenting reinforce our ongoing commitment to redefining treatment paradigms, improving on existing standards of care and addressing a diversity of patient and healthcare system needs.
  • The data at this years meeting exemplify Genentechs commitment to investing in its current portfolio to further improve patient outcomes.
  • Further information on the key abstracts featuring Genentech medicines that will be presented at ASH can be found in the table below.
  • Follow Genentech on Twitter via @Genentech and LinkedIn and keep up to date with ASH Annual Meeting news and updates by using the hashtag #ASH22.

Roche introduces the navify brand for its digital health solutions at HLTH 2022

Retrieved on: 
Friday, November 4, 2022

Roche unifies its digital health portfolio under the navify brand, providing a range of next generation software solutions.

Key Points: 
  • Roche unifies its digital health portfolio under the navify brand, providing a range of next generation software solutions.
  • The navify digital solutions reinforce Roche's commitment to help providers and innovators connect with patients for better access, experience and delivery of care.
  • BASEL, Switzerland, Nov. 4, 2022 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today at the HLTH 2022 meeting in Las Vegas, NV, US, that its digital health portfolio will now be available under the navify brand.
  • navify Oncology portfolio, navify Diagnostic Optimization, navify Infection Management, navify Algorithm Suite, and navify Kidney Companion).

Roche introduces the navify brand for its digital health solutions at HLTH 2022

Retrieved on: 
Friday, November 4, 2022

Roche unifies its digital health portfolio under the navify brand, providing a range of next generation software solutions.

Key Points: 
  • Roche unifies its digital health portfolio under the navify brand, providing a range of next generation software solutions.
  • The navify digital solutions reinforce Roche's commitment to help providers and innovators connect with patients for better access, experience and delivery of care.
  • BASEL, Switzerland, Nov. 4, 2022 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today at the HLTH 2022 meeting in Las Vegas, NV, US, that its digital health portfolio will now be available under the navify brand.
  • navify Oncology portfolio, navify Diagnostic Optimization, navify Infection Management, navify Algorithm Suite, and navify Kidney Companion).

Global Self-Testing Kits Market Trends and Forecasts Report, 2019-2021 & 2022-2027 Featuring Major Manufacturers - Abbott, ACON Laboratories Inc., Roche, Assure Tech and AdvaCare Pharma - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 2, 2022

The "Global Self-Testing Kits Market Trends and Forecasts" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Self-Testing Kits Market Trends and Forecasts" report has been added to ResearchAndMarkets.com's offering.
  • The current report will provide an in-depth look at the self-testing kits market.
  • This report analyzes the market trends of self-testing kits with data from 2021, estimates from 2022, and projections of compound annual growth rates (CAGRs) through 2027 (forecast period 2022-2027) and examines regional markets for self-testing kits.
  • Major manufacturers of self-testing kits include Abbott, ACON Laboratories Inc., Roche Holding AG, Assure Tech (Hangzhou) Co. Ltd. and AdvaCare Pharma LLP.

Curis to Release Third Quarter 2022 Financial Results and Hold Conference Call on November 9, 2022

Retrieved on: 
Wednesday, November 2, 2022

Management will host a conference call on the same day at 4:30 p.m.

Key Points: 
  • Management will host a conference call on the same day at 4:30 p.m.
  • To access the live conference call, please dial (888) 346-6389 fromthe United Statesor (412) 317-5252 from other locations, shortly before4:30 p.m.
  • The conference call can also be accessed on the Curis website at www.curis.com in the 'Investors' section.
  • A replay of the financial results conference call will be available on the Curis website shortly after completion of the call.

BioLabs and LabCentral Win 2022 Prix Galien USA Award

Retrieved on: 
Tuesday, November 1, 2022

CAMBRIDGE, Mass., Nov. 1, 2022 /PRNewswire/ -- BioLabs and LabCentral were chosen as the winner of the 2022 Prix Galien USA Awards, a prestigious award often regarded as the "Nobel Prize in the life sciences industry." The biotech startup launchpads were honored as the best in the new "Incubators, Accelerators and Equity" category at the Galien Foundation's Prix Galien USA Awards Ceremony last week in New York City.

Key Points: 
  • Prestigious award honors the life sciences startup launchpads as bestinnew "Incubators, Accelerators and Equity"category
    CAMBRIDGE, Mass., Nov. 1, 2022 /PRNewswire/ -- BioLabs and LabCentral were chosen as the winner of the 2022 Prix Galien USA Awards, a prestigious award often regarded as the "Nobel Prize in the life sciences industry."
  • The biotech startup launchpads were honored as the best in the new "Incubators, Accelerators and Equity" category at the Galien Foundation's Prix Galien USA Awards Ceremony last week in New York City.
  • BioLabs and LabCentral were selected as the winner among nearly 20 nominees in the "Incubators, Accelerators, and Equity" category, by the Galien Foundation's USA Committee.
  • The Prix Galien was created in 1970 by Roland Mehl in honor of Galien, the father of medical science and modern pharmacology.

LUNGevity Foundation's No One Missed Campaign Celebrates Second Year of #KnowYourBiomarker Storytelling Initiative to Drive Awareness of Comprehensive Biomarker Testing in Lung Cancer

Retrieved on: 
Tuesday, November 1, 2022

WASHINGTON, Nov. 1, 2022 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, today celebrates the second year of its #KnowYourBiomarker social media initiative as part of the No One Missed campaign aimed at driving awareness of comprehensive biomarker testing in non-small cell lung cancer (NSCLC).

Key Points: 
  • "Time and time again, we've heard stories from people living with lung cancer about the difference comprehensive biomarker testing has made for their treatment journey," said Andrea Ferris, president and CEO of LUNGevity Foundation.
  • Here are two examples of people living with lung cancer who shared their biomarker testing experiences as part of the #KnowYourBiomarker initiative.
  • This is a philosophy she applied when faced with a stage IV lung cancer diagnosis in 2018 at age 52.
  • LUNGevity Foundation is the nation's leading lung cancer organization focused on improving outcomes for people with lung cancer.

Lineage Cell Therapeutics Appoints Jill Howe as Chief Financial Officer

Retrieved on: 
Monday, October 31, 2022

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Jill Howe will join as the Companys Chief Financial Officer, effective November 14, 2022.

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Jill Howe will join as the Companys Chief Financial Officer, effective November 14, 2022.
  • Jill is a wonderful addition to our executive team as we work to establish Lineage as a leader in cell therapy and cell transplant medicine, stated Brian M. Culley, Lineage CEO.
  • Ms. Howe most recently served as Chief Financial Officer of DTx Pharma , a biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease.
  • Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs.

EQS-News: Most Active On The OTC Markets In September – A Look Back As October Comes To A Close

Retrieved on: 
Friday, October 28, 2022

OTC Markets Group Inc.s (OTCQX: OTCM) regulated markets experienced a slight increase in total monthly volume, recording $39.5 billion in September compared to $39.3 billion in August.

Key Points: 
  • OTC Markets Group Inc.s (OTCQX: OTCM) regulated markets experienced a slight increase in total monthly volume, recording $39.5 billion in September compared to $39.3 billion in August.
  • The OTCQX Best Market recorded $7.3 billion in trading volume in September, a slight increase over the $6.9 billion traded in August .
  • Like the OTCQX Best Market, the OTCQB Venture Markets top 10 Most Active list for the month saw new entries.
  • Below are the top 10 most actively traded securities on the OTCQX Best Market and OTCQB Venture Market in September.